This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lewis, J. E. Search for Related Content PubMed PubMed Citation Articles by Lewis, J. E. Social Bookmarking                         What's this?

Long-Term Use of Gemfibrozil (Lopid®) in the Treatment of Dyslipidemia

Sunnyvale Medical Clinic 596 Carroll St. Sunnyvale, California 94086

This report describes the results of long-term treatment for blood lipid regulation with a new drug, gemfibrozil (Lopid®). During a short-term placebo-controlled phase, gemfibrozil had significantly reduced triglycerides, VLDL-cholesterol, and total LDL-cholesterol, and had significantly increased HDL-cholesterol and the HDL-cholesterol to total cholesterol ratio. It had not, however, greatly affected total cholesterol and LDL-cholesterol. In the long term phase of the study the improvement attained during the controlled phase was maintained. More important, the lipoprotein values that had not shown improvement in the controlled phase showed definite beneficial changes. The types and incidence of adverse reactions during the long term treatment were similar to those observed during the controlled period. The results of the study indicate that gemfibrozil is effective and relatively safe for the long term treatment of lipid irregularities.

Angiology, Vol. 33, No. 9, 603-612 (1982)
DOI: 10.1177/000331978203300906


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?